Ortataxel manufacturers
- Ruzasvir
-
- $163.00
-
2026-07-27
- CAS:1613081-64-3
- Purity: 99.93%
- Supply Ability: 10g
|
| | Ortataxel Basic information |
| Product Name: | Ortataxel | | Synonyms: | DIMETHYL ((2S,2S)-((2S,2S)-(((S)-6-(2-CYCLOPROPYLTHIAZOL-5-YL)-1-FLUORO-6H-BENZO[5,6][1,3]OXAZINO[3,4-A]INDOLE-3,10-DIYL)BIS(1H-IMIDAZOLE-5,2-DIYL))BIS(PYRROLIDINE-2,1-DIYL))BIS(3-METHYL-1-OXOBUTANE-1,2-DIYL))DICARBAMATE;Ruzasvir (MK-8408);RuzasvirQ: What is
Ruzasvir Q: What is the CAS Number of
Ruzasvir;Carbamic acid, N,N'-[[(6S)-6-(2-cyclopropyl-5-thiazolyl)-1-fluoro-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester | | CAS: | 1613081-64-3 | | MF: | C49H55FN10O7S | | MW: | 947.09 | | EINECS: | | | Product Categories: | | | Mol File: | 1613081-64-3.mol |  |
| | Ortataxel Chemical Properties |
| density | 1.52±0.1 g/cm3(Predicted) | | pka | 11.22±0.46(Predicted) |
| | Ortataxel Usage And Synthesis |
| Uses | Ruzasvir (MK-8408) is an orally active inhibitor for genotypic HCV nonstructural protein 5A (NS5A), which inhibits the replication of NS5A mutants GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a and GT4a with EC90 ranging from 0.003 to 0.067 nM. Ruzasvir exhibits good pharmacokinetic characters in rhesus monkey model[1]. | | References | [1] Tong L, et al., Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. J Med Chem. 2017 Jan 12;60(1):290-306. DOI:10.1021/acs.jmedchem.6b01310 |
| | Ortataxel Preparation Products And Raw materials |
|